IUPAC/Chemical Name
N-Acetyl-S-(2-(4-chlorophenoxy)-2-methylpropionyl)homocystein
InChi Key
FPCXDWYBOVVFFE-ZDUSSCGKSA-N
InChi Code
InChI=1S/C16H20ClNO5S/c1-10(19)18-13(14(20)21)8-9-24-15(22)16(2,3)23-12-6-4-11(17)5-7-12/h4-7,13H,8-9H2,1-3H3,(H,18,19)(H,20,21)/t13-/m0/s1
SMILES Code
O=C(O)[C@H](CCSC(C(C)(OC1=CC=C(Cl)C=C1)C)=O)NC(C)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
373.85
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Takagi A, Sai K, Umemura T, Hasegawa R, Kurokawa Y. Relationship between hepatic peroxisome proliferation and 8-hydroxydeoxyguanosine formation in liver DNA of rats following long-term exposure to three peroxisome proliferators; di(2-ethylhexyl) phthalate, aluminium clofibrate and simfibrate. Cancer Lett. 1990 Aug;53(1):33-8. doi: 10.1016/0304-3835(90)90007-k. PMID: 2397479.
2: Teoh PC, Ransome GA. Primary type V hyperlipoproteinaemia (mixed hyperlipaemia): successful response to dietary restriction and simfibrate. Singapore Med J. 1974 Jun;15(2):149-52. PMID: 4370285.
3: Hayashi K. Influence of fibrates on ethanol metabolism in rats. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2000 Oct;35(5):306-20. PMID: 11144151.
4: Watanabe T, Suga T. Studies on peroxisomes. IX. Biochemical effects of simfibrate on precursor incorporation into polypeptide associated with peroxisome proliferation in rat liver. J Biochem. 1980 Jun;87(6):1595-601. doi: 10.1093/oxfordjournals.jbchem.a132902. PMID: 7400111.
5: Harvengt C, Desager JP. Pharmacokinetics and bioavailability of simfibrate a new clofibric acid derivative. Curr Ther Res Clin Exp. 1976 Jan;19(1):145-151. PMID: 812660.
6: De Rosa G, Savi L, De Rosa E, Pola P, Boni P. Valutazione clincio-terapeutica del simfibrato in comparazione con il clofibrato in pazienti aterosclerotici [Clinical and therapeutic evaluation of simfibrate compared toclofibrate in atherosclerotic patients]. Clin Ter. 1979 Feb 15;88(3):267-79. Italian. PMID: 376218.
7: Yamanaka H, Shimazaki J, Koya A, Mayuzumi T, Imai K. Effect of hypolipidemia on testosterone-stimulated prostatic growth in castrated rats. Endocrinol Jpn. 1977 Apr;24(2):213-7. doi: 10.1507/endocrj1954.24.213. PMID: 872822.
8: Cavallini L, Lucchetti G, Marchi S, Guglielmini R. Attività del simfibrato sulla lipoproteinlipasi post-eparinica [Action of simfibrate on post-heparin lipoprotein lipase]. Clin Ter. 1980 Jan 15;92(1):25-31. Italian. PMID: 7004746.
9: Gragnoli G, Tanganelli I, Signorini AM, Kristodhullu A. Azione ipolipemizzante del simfibrato nei soggetti affetti da diabete mellito [Hypolipidemic action of simfibrate in diabetic subjects]. Clin Ter. 1981 Feb 28;96(4):397-408. Italian. PMID: 7214862.
10: Sano T, Motomiya T, Yamazaki H. Influence of lipids metabolism on platelet activation in vivo. Thromb Res. 1983 Sep 1;31(5):675-84. doi: 10.1016/0049-3848(83)90098-1. PMID: 6417824.
11: Takagi A, Sai K, Umemura T, Hasegawa R, Kurokawa Y. Hepatomegaly is an early biomarker for hepatocarcinogenesis induced by peroxisome proliferators. J Environ Pathol Toxicol Oncol. 1992 May-Jun;11(3):145-9. PMID: 1625184.
12: Kurokawa Y, Takamura N, Matushima Y, Imazawa T, Hayashi Y. Promoting effect of peroxisome proliferators in two-stage rat renal tumorigenesis. Cancer Lett. 1988 Dec 1;43(1-2):145-9. doi: 10.1016/0304-3835(88)90227-3. PMID: 3203323.
13: Richmond BK. Response to: Laparoscopic cholecystectomy is safe and effective for the treatment of biliary dyskinesia in the pediatric population. Am Surg. 2010 Dec;76(12):1426. PMID: 21265362.
14: Yoshikuni Y, Chokai S, Ozaki T, Yoshida H, Nakane M, Kuwabara K. Hypolipidemic effect of NS-1 and other related drugs in rhesus monkeys. Atherosclerosis. 1988 Nov;74(1-2):149-56. doi: 10.1016/0021-9150(88)90201-8. PMID: 3214474.
15: Hattori T, Nagamatsu T, Ito M, Suzuki Y. The possible roles of hyperlipidemia and mononuclear cells in glomeruli in puromycin aminonucleoside nephrosis in rats. Jpn J Pharmacol. 1996 Jan;70(1):25-33. doi: 10.1254/jjp.70.25. PMID: 8822086.
16: Pioda GB, Del Favero A, Rambotti P. Aplasia midollare associata a trattamento con ticlopidina in soggetto con ipotiroidismo idiopatico [Bone marrow aplasia associated with ticlopidine treatment in a patient with idiopathic hypothyroidism]. Clin Ter. 1989 Sep 30;130(6):337-40. Italian. PMID: 2530035.
